Press Releases

 
Press Releases
  Date Title and Summary View
Apr 6, 2017
CRANBURY, N.J., April 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, is supporting several activities during Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated the month of April to honor and recognize those who...
PDF
Apr 3, 2017
Target Exceeded with More than 160 Patients Enrolled Top-Line Data on Track for 3Q17 CRANBURY, N.J., April 03, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, has completed enrollment in the ongoing Phase 3 clinical study (ESSENCE) of the ...
PDF
Mar 8, 2017
CRANBURY, N.J. and MILAN, Italy, March 08, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in Italy following the final publication of reimbursement guidelines by the Ministry of Health (M...
PDF
Mar 2, 2017
CRANBURY, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that management will present at two upcoming investor conferences. John Crowley, Chairman and Chief Executive Officer, will present at the Cowen & Com...
PDF
Mar 1, 2017
Growing Momentum for EU Galafold (Migalastat) Launch for Fabry Disease Tracking Toward 300 Patients by Year-End 2017  Target Enrollment Achieved in Phase 1/2 Pompe Study - Additional Data Expected in 2Q17 and 3Q17 Phase 3 EB Program Remains on Track for Topline Data in Mid-2017 CRANBURY, N.J., March 01, 2017 (GLOBE NEWSWIRE) -- Amicus Ther...
PDF
Feb 27, 2017
National Institute for Health and Care Excellence (NICE) Publishes Final Guidance Covering Reimbursement of Galafold for Fabry Disease CRANBURY, N.J., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the pr...
PDF
Feb 22, 2017
CRANBURY, N.J., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Wednesday, March 1, 2017 at 8:30 a.m. ET to discuss financial results for the year ended December 31, 2016. ...
PDF
Feb 15, 2017
Biomarkers of Muscle Damage (AST, ALT and CK) Demonstrate Improving Trends in Majority of Patients Biomarker of Key Disease Substrate (Hex4) Demonstrates Improving Trend in All Patients Safety Data Continue to Show No Infusion-AssociatedReactions Following 150+ Infusions CRANBURY, N.J. and SAN DIEGO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Ami...
PDF
Feb 15, 2017
Scientific Findings Reveal that Cellular Damage Alters Trafficking for Key Proteins Involved in Muscle Membrane Integrity and Muscle Repair Preclinical Studies Demonstrate Reversal of Cellular Damage and Significant Improvements in Muscle Strength in GAA Knock-out Mice After Treatment with Amicus Novel Pompe Treatment Paradigm Additional ...
PDF
Feb 14, 2017
New Phase 3 Retrospective Analysis Shows Correlation between Reduction in Disease Substrate (Kidney Interstitial Capillary GL-3) and Improved Diarrhea in Fabry Patients with Amenable Mutations treated with Migalastat Supportive Study for Japanese New Drug Application (J-NDA) Demonstrates Migalastat Exposure is Similar in Japanese and non-Japan...
PDF
Page:
1
... NextLast